Breast Cancer clinical trials
Showing 51–100 of 1,067 active trials. Describe your situation to see which ones you may be eligible for.
- Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer
- Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
- Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
- Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
- Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Breast Mesh Used in Two-staged Breast Reconstruction
- PRE-I-SPY Phase I/Ib Oncology Platform Program
- Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
- Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.
- Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer
- Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
- A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
- A Study of Surgery and Radiotherapy in People With Breast Cancer
- Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
- Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy
- Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
- FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
- A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
- ATEMPT 2.0: Adjuvant T-DM1 vs TH
- Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
- Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer
- A Study of HLD-0117 in Patients With Metastatic Breast Cancer
- CBD for Breast Cancer Primary Tumors
- Time Restricted Eating During Chemotherapy for Breast Cancer
- Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
- Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
- DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
- Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
- NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
- A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
- Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
- A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
- SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
- Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
- A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery
- Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon
- 5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
- The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
- Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
- Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
- Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
- Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.